Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome.
Eng L, Azad AK, Qiu X, Kong QQ, Cheng D, Ying N, Tse A, Kuang Q, Dodbiba L, Renouf DJ, Marsh S, Savas S, Mackay HJ, Knox JJ, Darling GE, Wong RK, Xu W, Liu G, Faluyi OO. Eng L, et al. Among authors: mackay hj. Carcinogenesis. 2015 Sep;36(9):956-62. doi: 10.1093/carcin/bgv073. Epub 2015 May 25. Carcinogenesis. 2015. PMID: 26014353
A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia.
Mackay HJ, Buckanovich RJ, Hirte H, Correa R, Hoskins P, Biagi J, Martin LP, Fleming GF, Morgan R, Wang L, Polintan R, Oza AM. Mackay HJ, et al. Gynecol Oncol. 2012 Apr;125(1):136-40. doi: 10.1016/j.ygyno.2011.11.042. Epub 2011 Dec 2. Gynecol Oncol. 2012. PMID: 22138373 Free PMC article. Clinical Trial.
Validation of microRNA pathway polymorphisms in esophageal adenocarcinoma survival.
Faluyi OO, Eng L, Qiu X, Che J, Zhang Q, Cheng D, Ying N, Tse A, Kuang Q, Dodbiba L, Renouf DJ, Marsh S, Savas S, Mackay HJ, Knox JJ, Darling GE, Wong RK, Xu W, Azad AK, Liu G. Faluyi OO, et al. Among authors: mackay hj. Cancer Med. 2017 Feb;6(2):361-373. doi: 10.1002/cam4.989. Epub 2017 Jan 11. Cancer Med. 2017. PMID: 28074552 Free PMC article.
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.
Mackay HJ, Au HJ, McWhirter E, Alcindor T, Jarvi A, MacAlpine K, Wang L, Wright JJ, Oza AM. Mackay HJ, et al. Invest New Drugs. 2012 Jun;30(3):1158-63. doi: 10.1007/s10637-011-9650-4. Epub 2011 Mar 12. Invest New Drugs. 2012. PMID: 21400081 Clinical Trial.
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.
Diaz-Padilla I, Wilson MK, Clarke BA, Hirte HW, Welch SA, Mackay HJ, Biagi JJ, Reedijk M, Weberpals JI, Fleming GF, Wang L, Liu G, Zhou C, Blattler C, Ivy SP, Oza AM. Diaz-Padilla I, et al. Among authors: mackay hj. Gynecol Oncol. 2015 May;137(2):216-22. doi: 10.1016/j.ygyno.2015.03.005. Epub 2015 Mar 11. Gynecol Oncol. 2015. PMID: 25769658 Clinical Trial.
Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.
Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, Mackay HJ, Mazurka J, Sederias J, Ivy P, Dancey JE, Eisenhauer EA. Oza AM, et al. Among authors: mackay hj. J Clin Oncol. 2011 Aug 20;29(24):3278-85. doi: 10.1200/JCO.2010.34.1578. Epub 2011 Jul 25. J Clin Oncol. 2011. PMID: 21788564 Free PMC article. Clinical Trial.
98 results